Bridgewater Advisors’s GSK GSK Stock Holding History

Bridgewater Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$290K	Sell	5,630 -8	-0.1%	-$423	0.02%	383
2026 Q1	$287K	Buy	5,638 +180	+3%	+$9.75K	0.02%	374
2025 Q4	$262K	Sell	5,458 -87	-2%	-$4.06K	0.02%	381
2025 Q3	$261K	Buy	+5,545	New	+$217K	0.02%	380

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bridgewater Advisors's GSK Position: Q2 2026 in Review

Bridgewater Advisors reduced its GSK (GSK) stake by 0.14% in Q2 2026, selling an estimated $423 and leaving 5,630 shares worth $290K. The position accounts for 0.02% of the portfolio, ranked #383.

Bridgewater Advisors first reported a position in GSK in Q3 2025 and has held it in 4 quarters since. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Bridgewater Advisors held 5,630 shares of GSK worth $290K as of Q2 2026.
Bridgewater Advisors sold 8 GSK shares in Q2 2026, an estimated $423.
GSK made up 0.02% of Bridgewater Advisors's portfolio in Q2 2026, its #383 holding.
Bridgewater Advisors first reported a position in GSK in Q3 2025 and has held it in 4 quarters since.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Bridgewater Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.